Generic Name and Formulations:
Hepatitis A vaccine, inactivated 25Units per 0.5mL (pediatric/adolescent), or 50Units per 1mL (adult); susp for IM inj; aluminum adsorbed; preservative-free.
Merck & Co., Inc.
Indications for VAQTA:
Hepatitis A immunization.
≥19 yrs: 1mL IM at elected date and booster dose (1mL IM) 6–18 months later.
<12 months: not recommended. 1–18 yrs: 0.5mL IM at elected date and booster dose (0.5mL IM) 6–18 months later.
Have epinephrine (1:1000) available. Latex allergy. Inject into deltoid muscle, preferably at least 2 weeks before expected exposure. If given with immune globulin, use separate syringe and different site. Fever. Malignancies. Immunocompromised (may have suboptimal response). Bleeding disorders. Pregnancy (Cat.C). Nursing mothers.
Immunosuppressives may reduce efficacy. Concomitant vaccines, immune globulins: see literature.
Injection site reactions (esp. pain, tenderness), headache, fever, GI upset, myalgia, abdominal pain, rash, pharyngitis and other upper respiratory tract effects.
Prefilled syringes (0.5mL, 1mL)—1, 5; Single-dose vials (0.5mL)—1, 10; Single-dose vials (1mL)—1, 5, 10
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Oxidized Low-Density Lipoprotein May Predict Risk for Recurrent Stroke
- Inappropriate Prescribing Protocols in Parkinson Disease
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Congress Passes Bill to Fight Opioid Crisis